

Advanced Medical Technology Association

BRINGING INNOVATION TO PATIENT CARE WORLDWIDE

About AdvaMed





- World's largest medical technology association
- 1,600+ member companies and subsidiaries



- Members produce 90% of sales in domestic market, 50% of sales in global market
 - 70%+ of member companies have less than
 \$30 million in annual revenue



- 65 staff with global expertise, bi-partisan backgrounds
- 45 member Board of Directors including 5 from smaller companies

Comparative Clinical Effectiveness Research: Impact on Industry



• Facilitate diffusion of valuable products

• Winners and losers

• Overall: Good for industry

Comparative Effectiveness Research and the Device Industry: Some Cautions




• Time dimension

• Evolving evidence

• Few "slam dunks"

Angioplasty reduces angina, opens blockages: change in value over time





"Technological Development and Medical Productivity: Diffusion of Angioplasty in New York State," Cutler D, Huckman, R; National Bureau of Economic Research, Oct 2002

©NEMA 2005

ICD: Example of pace of innovation






98% effective 99% reliable ²

Cost/day of ICD therapy has <u>decreased</u>:

- 1. Reduced procedure time (12 to 2 days)
- 2. Increased battery life (1 to 9 years)
- 3. Improved device therapy (4x therapies)
- 4. Better medical outcomes (multi. studies)



¹ Zipes DP. Circulation. July 1,1995;92(1):59-65.

² Medtronic CRDM Product Performance Report, Second Edition - Issue 55, August, 2006.

Application of research to coverage and payment



- Should not be used to deny or reduce payments for safe and effective treatments, *especially* innovative treatments
 - -Ignores differences between patients
 - -Penalizes evolving treatments
 - -Can stifle innovation
- Could be used for

-Development of quality standards for use in pay for performance systems

-Professional treatment guidelines

-Indirectly impact behavior in payment systems that reward quality and efficiency

Cost Effectiveness: Wrong prescription for industry & patients



- Flawed methodology
- Denies patients quality care
- Stifles innovation

Valuing a Human Life through "Quality Adjusted Life Years" (QUALY)



Valuing a Life

- Willing to pay for airbags
- Pay differential between risky and safer occupations

"Quality-Adjusting" a Life

- Respondent rating
- Time trade-off
- "Standard gamble"

Quality Adjusted Life Years: Theoretical Issues



- Do we really want to make treatment decisions based on a \$ value for human life?
- Subjectivity of estimates: \$30,000-\$200,000+
- Difficulty of translating clinical data to QUALYs
 ⇒Estimates of QUALY from ICDs: \$18,000-\$569,000
- Discriminates against disabled and elderly
- Does not reflect numerous social values: reduction in uncertainty, maintenance of function
- Does not reflect differences in patient preferences, especially of those who are sick or disabled

The NICE "Model"



- No coverage for effective but high cost cancer drugs for terminal patients
- No coverage (until recently) for any drugs for MS
- No coverage for one-half of osteoporosis drugs available in U.S.
- No coverage for macular degeneration treatments unless already lost sight in one eye
- No coverage for Alzheimer drugs in early disease stage

Cost Effectiveness and Innovation



• Makes breakthroughs less likely

• Makes progress by cumulative change less likely

Venture Capital Funding: Critical to Innovation



VC Funded Medical Breakthroughs


- Angioplasty
- Minimally invasive bypass
- Glucose selfmonitoring
- Implantable defibrillators
- Joint replacement
- Doppler ultrasound

Minimally invasive biopsy

- •PSA
- •MRI
- •TPA
- •Electro-ablation
- •Epogen
- •Enbril
- •Pulse oximeters

VC Funding: Sensitivity to Coverage/ Reimbursement





[1] See *Fueling Innovation In Medical Devices (And Beyond): Venture Capital IN Health Care*, by D. Clay Ackerly, Ana M. Valverde, Lawrence W. Diener, Kristin L Dossary, and Kevin A Schulman, for additional data indicating close link between reimbursement and venture capital funding.



Advanced Medical Technology Association

BRINGING INNOVATION TO PATIENT CARE WORLDWIDE